Exploratory Profiling of Extracellular MicroRNAs in Cerebrospinal Fluid Comparing Leptomeningeal Metastasis with Other Central Nervous System Tumor Statuses

• Published in: Journal of clinical medicine Vol. 10; no. 21; p. 4860
• Main Authors: Im, Ji Hye, Kim, Tae Hoon, Lee, Kyue-Yim, Gwak, Ho-Shin, Lin, Weiwei, Park, Jong Bae, Kim, Jong Heon, Yoo, Byong Chul, Park, Seong-Min, Kwon, Ji-Woong, Shin, Sang Hoon, Yoo, Heon
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 22.10.2021; MDPI
• Subjects: Biomarkers; Brain cancer; Cellular biology; Cerebrospinal fluid; Clinical medicine; Diagnostic tests; Gene expression; Magnetic resonance imaging; Medical prognosis; Metastasis; MicroRNAs; Nervous system; Pathogenesis; Patients; Tumors; United States > US
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm10214860

The diagnosis of leptomeningeal metastasis (LM) is often difficult due to the paucity of cancer cells in cerebrospinal fluid (CSF) and nonspecific findings on neuroimaging. Investigations of extracellular microRNAs (miRNAs) in CSF could be used for both the diagnosis and study of LM pathogenesis because they reflect the activity of disseminating cancer cells. We isolated CSF extracellular miRNAs from patients (n = 65) of different central nervous system tumor statuses, including cancer control, healthy control, LM, brain metastasis (BM), and primary brain tumor (BT) groups, and performed miRNA microarrays. In unsupervised clustering analyses, all LM and two BM samples showed unique profiles. Among 30 miRNAs identified for LM-specific biomarkers via a Prediction Analysis of Microarrays, miR-335-5p and miR-34b-3p were confirmed in both the discovery and validation samples (n = 23). Next, we performed a significance analysis of the microarray (SAM) to extract discriminative miRNA profiles of two selected CSF groups, with LM samples revealing a greater number of discriminative miRNAs than BM and BT samples compared to controls. Using SAM comparisons between LM and BM samples, we identified 30 upregulated and 6 downregulated LM miRNAs. To reduce bias from different primary cancers, we performed a subset analysis with primary non-small cell lung cancer, and 12 of 13 upregulated miRNAs in LM vs. BM belonged to the upregulated miRNAs in LM. We identified possible target genes and their biological processes that could be affected by LM discriminative miRNAs in NSCLC using the gene ontology database. In conclusion, we identified a unique extracellular miRNA profile in LM CSF that was different from BM, suggesting the use of miRNAs as LM biomarkers in studies of LM pathogenesis.